A US health service has questioned the outcome of a new study of AstraZeneca’s corona vaccine.
Experts who oversaw the study fear the pharmaceutical may have used outdated information, the National Institute of Allergies and Infectious Diseases (NIAID) says. This may give an “incomplete” picture of the efficacy of the vaccine.
AstraZeneca had announced the outcome of the extensive study involving tens of thousands of volunteers on Monday.
According to that data, the corona vaccine was 79 percent effective in preventing disease. There would also be no indications that there is an increased risk of blood clots.
The AstraZeneca vaccine is already in use in Europe, but not yet in the United States.
The NIAID, the organization of immunologist Anthony Fauci, is calling on the pharmaceutical company to work well with the committee overseeing the study and to ensure that the most “accurate and recent” figures are released as soon as possible.
